Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CES2 | O00748 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | LPAR3 | Q9UBY5 | 5/20 | 0.39 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.39 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.39 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3913988 | 0.92 | LPAR3 (0.45) | HTTMEN1THRBKMT2AMAPT | |
| SCHEMBL9660836 | 0.92 | LPAR3 (0.45) | HTTMEN1THRBKMT2AMAPT | |
| SCHEMBL700752 | 0.92 | LPAR3 (0.45) | HTTMEN1THRBKMT2AMAPT | |
| SCHEMBL700802 | 0.92 | LPAR3 (0.45) | HTTMEN1THRBKMT2AMAPT | |
| SCHEMBL700500 | 0.92 | LPAR3 (0.45) | HTTMEN1THRBKMT2AMAPT | |
| SCHEMBL9660637 | 0.92 | LPAR3 (0.45) | HTTMEN1THRBKMT2AMAPT | |
| SCHEMBL6470248 | 0.92 | LPAR3 (0.45) | HTTMEN1THRBKMT2AMAPT | |
| SCHEMBL706907 | 0.89 | — | — | |
| SCHEMBL702719 | 0.83 | — | — | |
| SCHEMBL1689825 | 0.81 | LPAR3 (0.50) | MEN1KMT2AMAPTUSP2LPAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156545-A1 | Substituted Phosphate Esters of Nucleoside Phosphonates | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2009-06-18 | — | — | US | disclosed |
| WO-2006130217-A2 | SUBSTITUTED PHOSPHATE ESTERS OF NUCLEOSIDE PHOSPHONATES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156545-A1 | Substituted Phosphate Esters of Nucleoside Phosphonates | PNP, TYMP, ENPP1 | HTT 3456/4885MEN1 2049/4885THRB 2027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.